TELA Bio to Announce First Quarter 2023 Financial Results
TELA Bio, Inc. (NASDAQ: TELA), a leading medical technology company, has announced that it will release its first quarter 2023 financial results on May 11, 2023. The management will host a conference call at 4:30 p.m. ET to discuss these results and provide a corporate update. TELA Bio specializes in innovative soft-tissue reconstruction solutions, aiming to enhance clinical outcomes while preserving the patient's anatomy. Interested investors can register to listen to the call online, with options for a replay available post-event. The company emphasizes its commitment to advanced, economically effective solutions that leverage patients' natural healing responses.
- Upcoming conference call and financial results announcement may indicate transparency and investor engagement.
- None.
MALVERN, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the company will report first quarter 2023 financial results on Thursday, May 11, 2023. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
Conference Call and Webcast Details
Investors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the start of the call. A replay of the webcast can be accessed via the Events & Presentations page of the investor section of TELA's website.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact
Greg Chodaczek
332-895-3230
ir@telabio.com
FAQ
When will TELA Bio report its Q1 2023 financial results?
What time is TELA Bio's conference call regarding Q1 2023 financial results?
How can I listen to the TELA Bio conference call?
What is the focus of TELA Bio's business?
